Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Luye Considering $500 Million Singapore IPO for Healthcare Assets

publication date: Jan 25, 2018

Luye Medical, the healthcare arm of Luye Life Sciences, is considering an IPO in Singapore that could raise as much as $500 million. The company has assembled a portfolio of businesses, largely through M&A, consisting of hospitals, clinics and diagnostic services that spreads across China, Australia and Singapore. It is based in Singapore. Luye Pharma, which is also part of Luye Life Sciences, is the parent's listed pharmaceutical subsidiary. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China